Yiling Pharmaceutical reported on Tuesday the receipt of the official drug certificate for its newly-developed drug Yishen Yangxin Anshen Tablet for treating insomnia from China's National Medical Products Administration (NMPA).

The company's Yishen Yangxin Anshen Tablet offers a new treatment for insomnia with the symptoms of sleeplessness, frequent dreams during sleep, palpitation, lassitude, forgetfulness, dizziness, soreness and weakness of waist and knees.

Based on pharmacodynamics studies, the Yishen Yangxin Anshen Tablet can exert sedative and hypnotic effects and play a systematic regulatory role in improving sleep by protecting brain neurons in the hippocampal region, inhibiting the activation of hypothalamic-pituitary-adrenal (HPA) axis, improving stress state as well as improving memory and resist fatigue, said the company.

In conjunction with the company's randomized, double-blind, placebo-parallel-controlled and multi-centre clinical trial, Yishen Yangxin Anshen Tablet reduces insomnia-related symptoms, difficulty in falling asleep, easiness to wake up, early awakening and short sleep time.

Yishen Yangxin Anshen Tablet is reportedly the company's 12th innovative patent TCM with full intellectual property rights, covering cardio-cerebrovascular disease, diabetes, respiratory diseases, tumors, neurological diseases as well as urinary diseases treatments.